2,32,33 POTENTIAL FUTURE THERAPIES Given the elevated GLP-1 levels and robust insulin response to glucose observed in PGBH, blocking GLP-1 may provide clinical benefit
PlexusDx operates transparently with state medical boards across all 50 states, ensuring accountability and safety oversight
A 2021 analysis published in Cardiovascular Diabetology found that semaglutide produced significant reductions in triglycerides and total cholesterol alongside its weight loss effects, with improvements correlating strongly with the degree of weight lost (Husain et al., Cardiovascular Diabetology, 2021, Tirzepatide and Cholesterol: Does the Dual Mechanism Help More For patients with significant lipid abnormalities, tirzepatide may offer an advantage over semaglutide
Real health solutions require real science, professional oversight, and honesty
Mol Metab 2020;32:160167 [DOI] [PMC free article] [PubMed] [Google Scholar] 92